Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.54 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.54 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951691 | 0.85 | MET (0.69) | METCDKL5PDE1APDE4CPDE4D | |
| SCHEMBL1953334 | 0.85 | MET (0.76) | METCDKL5 | |
| SCHEMBL1952675 | 0.84 | MET (0.54) | METCDKL5 | |
| SCHEMBL3829046 | 0.84 | MET (0.66) | METCDKL5 | |
| SCHEMBL1951365 | 0.84 | MET (0.59) | METCDKL5PDE1APDE4CPDE4D | |
| SCHEMBL3825945 | 0.84 | MET (0.54) | METCDKL5 | |
| SCHEMBL1951338 | 0.84 | MET (0.56) | METCDKL5PDE1APDE4CPDE4D | |
| SCHEMBL1953313 | 0.82 | MET (0.74) | METCDKL5 | |
| SCHEMBL20052643 | 0.82 | MET (0.54) | METCDKL5PDE1APDE4CPDE4D | |
| SCHEMBL1951549 | 0.82 | MET (0.54) | METCDKL5PDE1APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | claimed |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE HOLDINGS CORPORATION | 2020-10-08 | — | — | US | claimed |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2018-10-04 | — | — | US | claimed |
| EP-2497470-B1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORP (US) | 2015-10-28 | — | — | EP | claimed |
| US-20130324515-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-12-05 | — | — | US | claimed |
| EP-2497470-A1 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | Incyte Corporation (US) | 2012-09-12 | — | — | EP | claimed |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-06-09 | — | — | US | claimed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | claimed |
| EP-2099447-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | Incyte Corporation (US) | 2009-09-16 | — | — | EP | claimed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | claimed |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION | 2025-07-10 | — | — | US | disclosed |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| US-7767675-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | INCYTE CORPORATION (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008064157-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002392-A1 | Imidazotriazines and Imidazopyrimidines as Kinase Inhibitors | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885PDE1A 1772/4885 |
| US-20180282340-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | MET 1/4885CDKL5 239/4885PDE1A 2140/4885 |
| US-20130324515-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885PDE1A 1772/4885 |
| US-20250223291-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885PDE1A 1772/4885 |
| US-20200317680-A1 | Imidazotriaines and Imidazopyrimidines as Kinase Inhibitors | MET, RET, ERBB2 | MET 1/4885CDKL5 239/4885PDE1A 2140/4885 |
| US-20110136781-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885PDE1A 1772/4885 |
| US-12084449-B2 | Imidazotriazines and imidazopyrimidines as kinase inhibitors | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885PDE1A 1772/4885 |
| US-20080167287-A1 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS | ERBB2, MERTK, ABL1 | MET 5/4885CDKL5 315/4885PDE1A 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.